Literature DB >> 7723356

Effects of chronic angiotensin I-converting enzyme inhibition on the relations between ventricular action potential changes and myocardial hypertrophy in aging rats.

P Kreher1, M T Ristori, B Corman, J Verdetti.   

Abstract

We studied the effect of aging on cardiac hypertrophy and action potential duration (APD) in normotensive male WAG/Rij rats and evaluated the role of the renin-angiotensin system (RAS) in these effects. Cardiac hypertrophy occurs in 30-month-old rats, as indicated by an increase in heart weight, and APD gradually increases with aging in the epicardial region of the right and the left ventricle. Short-term treatment (1 month) with the angiotensin-converting enzyme inhibitor (ACEI) perindopril prevented age-related increase in heart weight/body weight ratio independent of its antihypertensive effects, but did not prevent changes in APD in 30-month-old rats. Our results show a dissociation of changes in cardiac mass from changes in APD during aging. The effect of ACEI on hypertrophy may be due in part to a direct angiotensin effect on cellular growth. Changes in APD are not related to hypertrophy but rather to the process of aging.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7723356     DOI: 10.1097/00005344-199501000-00012

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

Review 1.  Renin-angiotensin system and cardiac aging.

Authors:  J Belmin
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

2.  Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy.

Authors:  B Corman; M Duriez; P Poitevin; D Heudes; P Bruneval; A Tedgui; B I Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

3.  Cardiomyopathy development protection after myocardial infarction in rats: Successful competition for major dihydropyridines' common metabolite against captopril.

Authors:  Katarzyna A Mitręga; Adrianna M Spałek; Jerzy Nożyński; Maurycy Porc; Magdalena Stankiewicz; Tadeusz F Krzemiński
Journal:  PLoS One       Date:  2017-06-21       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.